HR-Positive Breast Cancer Content

HR-Positive Breast Cancer

Leah LawrenceHR Breast Cancer | April 17, 2025

iDFS strongly correlates with OS in HR+/HER2- early breast cancer, supporting its use as a surrogate endpoint in trials.

Leah LawrenceHR Breast Cancer | April 7, 2025

Imlunestrant with or without abemaciclib improved PFS in ER+/HER2- advanced breast cancer post-endocrine therapy.

Brandon TwyfordHR Breast Cancer | April 5, 2025

Final results from the PENELOPE-B trial show palbociclib did not improve survival in high-risk HR+/HER2– breast cancer.

Yvette C. TerrieHR Breast Cancer | April 4, 2025

Camizestrant plus CDK4/6 inhibition significantly improved PFS in HR+/HER2– advanced breast cancer with ESR1 mutations.

Dr. Mik RinneHR Breast Cancer | July 19, 2024

Dr. Mik Rinne discusses a study on the efficacy of the CDK2 inhibitor BLU-222 in patients with HR+/HER2- breast cancer.